Mylan collaborates with CSIR for management of COVID-19


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ clinical-trials-well-proven-drugs-partnership-industry-towards-development-multiple-therapeutic-options-covid19
A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration

The Council of Scientific & Industrial Research (CSIR), India’s premier research organization, and Mylan Laboratories Limited, the India-based subsidiary of leading global pharmaceutical company Mylan, today announced a partnership to address unmet patient needs amidst the evolving COVID-19 pandemic. Under the partnership, CSIR’s constituent laboratory Indian Institute of Chemical Technology (CSIR-IICT), and Mylan will collaborate to identify potential therapies for COVID-19.

A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration. The first of the clinical trial to be rolled out is a multiple arm phase 3 study that will be conducted in adult patients with mild to moderate COVID -19 at risk of complications.

Director-General of CSIR, Dr Shehkar C Mande stated, “The current collaboration with Mylan is a significant milestone and during the current COVID-19 pandemic, CSIR has prioritized conducting clinical trials of well-proven drugs in partnership with industry towards the development of multiple therapeutic options for COVID-19.”

Director of CSIR-IICT, Dr Chandrasekhar said, “CSIR is delighted to associate with Mylan as knowledge and scientific partner, and looks forward to working with the company, especially given Mylan’s vast industry experience in clinical trials and commercialization.”

Mylan Chief Operating Officer, Sanjeev Sethi stated, “Our collaboration with CSIR is a strategic step forward aimed at identifying effective treatments for patients with COVID-19. In addition to bringing forward new indications, this partnership will also help us identify multiple molecules that can potentially be leveraged in therapies for various other infectious diseases in the future.”

The application for the clinical trials has been submitted to the Drugs Controller General of India (DCGI) for regulatory approval.

CSIR has appointed Dr Ram Vishwakarma, Honorary Advisor to DG-CSIR and former Director CSIR-IIIM (Indian Institute of Integrative Medicine) as a mentor to lead this collaboration.

The Council of Scientific & Industrial Research (CSIR), known for its cutting-edge R&D knowledgebase in diverse Science & Technology areas, is a contemporary and premier R&D organization. Having a pan-India presence, CSIR has a dynamic network of 38 national laboratories, 39 outreach centres, 3 Innovation Complexes and 5 units. CSIR covers a wide spectrum of science and technology – from oceanography, geophysics, chemicals, drugs, genomics, biotechnology and nanotechnology to mining, aeronautics, instrumentation, environmental engineering and information technology.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. It is one of the world's largest producers of active pharmaceutical ingredients.

Tags : #Mylan #CSIR #DCGI #SanjeevSethi #LatestPharmaCollaboration #DrRamVishwakarma

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

The Value of Risk Communication in Public HealthOctober 08, 2026
What Makes a Reliable Health Screening Programme?October 08, 2026
How Language Access Can Improve Patient Communication in Indian HealthcareOctober 07, 2026
Why Health Literacy Matters in Preventive HealthcareOctober 07, 2026
Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
How Community Health Workers Support Preventive Care DeliveryOctober 07, 2026
AI in India's Emergency Departments: Reducing Diagnostic DelaysOctober 06, 2026
AI and Patient Consent in India: Who Is Responsible?October 06, 2026
Wearable Technology in Pregnancy: Benefits and LimitsOctober 06, 2026
Remote Monitoring for High-Risk Pregnancies in IndiaOctober 06, 2026
Fortis Escorts Faridabad Launches ‘Sehat Express’ Mobile Bus for Accessible Doorstep Cancer Screening in association with Faridabad Industries Association Charitable Society and Rotary Club FaridabadOctober 05, 2026
Advanced Thrombectomy Saves 60-Year-Old Woman After Severe Heart Attack at KIMS SaveeraOctober 05, 2026
Constipation, Bloating and Long Sitting Hours: Doctors at RG Hospitals Delhi Warn Urban Professionals Not to Ignore Gut ProblemsOctober 05, 2026
Fermenta – Centre of Excellence for Food Fortification Inaugurated at NIFTEM-T, ThanjavurOctober 05, 2026
Alzheimer’s Dementia: Recognising the Signs, Diagnosing Earlier and Changing the Future of Brain HealthOctober 05, 2026
Man Matters Hairfall Case Study 2026: 7 Lakh+ Consultations Reveal How Hair Loss Changes With AgeOctober 05, 2026
Medication Reconciliation: A System-Level Step for Safer Transitions of CareOctober 05, 2026
The Role of Clinical Pharmacists in Safer Medication UseOctober 05, 2026
Nanavati Max Hospital Hosts Max Cancer Congress 2026, Bringing Together Oncology Experts to Explore the Future of Cancer Care October 01, 2026